Skip to main content

Table 1 Clinical characteristics of the subjects

From: Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study

Variables All (n = 35) Conventional group (n = 18) Sitagliptin group (n = 17)
0 month 0 month 12 months 24 months 0 month 12 months 24 months
Age, y 66.5 ± 8.9 64.1 ± 10.3    69.1 ± 6.5   
Male, n (%) 20 (57.1) 11 (61.1)    9 (52.9)   
Body mass index, kg/m2 27.0 ± 4.2 27.2 ± 5.0 27.1 ± 4.9 27.0 ± 4.8 26.8 ± 3.3 26.9 ± 3.3 26.5 ± 3.0
Systolic blood pressure, mm Hg 128.0 ± 13.1 127.2 ± 14.0 129.5 ± 15.3 123.6 ± 12.5 136.9 ± 16.7 138.6 ± 15.6 133.2 ± 13.3*
Diastolic blood pressure, mm Hg 72.8 ± 10.1 78.8 ± 10.6 75.4 ± 10.9 72.4 ± 10.2 79.8 ± 8.9 78.5 ± 8.8 76.5 ± 8.8
Heart rate, bpm 67.3 ± 9.5 67.1 ± 8.6 67.7 ± 10.3 67.9 ± 8.5 67.2 ± 9.6 65.6 ± 10.7 68.0 ± 12.9
Creatinine, μmol/L 72.0 ± 19.5 71.8 ± 19.3 70.5 ± 19.6 79.5 ± 24.6 72.2 ± 20.2 72.2 ± 22.7 76.8 ± 24.3
Total cholesterol, mmol/L 4.66 ± 0.75 4.74 ± 0.87 4.95 ± 1.19 4.72 ± 0.98 4.57 ± 0.60 4.57 ± 0.78 4.60 ± 0.69
Triglycerides, mmol/L 1.38 ± 0.48 1.49 ± 0.47 1.55 ± 0.53 1.19 ± 0.31 1.26 ± 0.47 1.26 ± 0.65 1.43 ± 0.97
HDL cholesterol, mmol/L 1.42 ± 0.37 1.38 ± 0.45 1.44 ± 0.40 1.45 ± 0.37 1.47 ± 0.27 1.46 ± 0.33 1.47 ± 0.34
Glucose, mmol/L 7.04 ± 1.11 7.03 ± 1.04 7.14 ± 1.46 6.66 ± 1.67 7.05 ± 1.21 6.66 ± 1.27 6.48 ± 0.81
HbA1c, % 7.0 ± 0.5 7.0 ± 0.6 6.6 ± 0.7 6.6 ± 0.7 7.0 ± 0.4 6.6 ± 0.3 6.6 ± 0.4
Brachial artery diameter, mm 4.08 ± 0.55 4.05 ± 0.60 4.02 ± 0.60 3.98 ± 0.58 4.11 ± 0.52 4.14 ± 0.59 4.19 ± 0.67
Current smoker, n (%) 5 (19.2) 5 (41.7)    0 (0)*   
Complications
Hypertension, n (%) 26 (74.3) 13 (72.2)    13 (76.5)   
Dyslipidemia, n (%) 25 (71.4) 11 (61.1)    14 (82.4)   
Coronary heart disease, n (%) 18 (51.4) 8 (44.4)    10 (58.8)   
Cerebrovascular disease, n (%) 3 (8.5) 2 (11.1)    1 (5.9)   
Antidiabetic drugs
Sulfonylurea, n (%) 10 (28.6) 5 (27.8) 6 (33.0) 6 (33.0) 5 (29.4) 3 (17.6) 3 (17.6)
Metformin, n (%) 9 (25.7) 5 (27.8) 7 (38.9) 7 (38.9) 4 (23.5) 5 (29.4) 5 (29.4)
α-Glucosidase inhibitor, n (%) 13 (37.1) 4 (22.2) 8 (44.4) 8 (44.4) 9 (52.9) 6 (35.3) 6 (35.3)
Pioglitazone, n (%) 4 (11.4) 2 (11.1) 3 (16.7) 3 (16.7) 2 (11.8) 1 (5.9) 1 (5.9)
Glinide, n (%) 1 (2.9) 0 (0) 1 (5.6) 1 (5.6) 1 (5.9) 0 (0) 0 (0)
Antihyperlipidemic drugs
Statin, n (%) 21 (60.0) 8 (44.4) 8 (44.4) 9 (50.0) 13 (76.4) 12 (70.1) 12 (70.1)
Fibrate, n (%) 2 (5.7) 2 (11.1) 2 (11.1) 2 (11.1) 0 (0) 0 (0) 0 (0)
Eicosapentaenoic acid, n (%) 2 (5.7) 1 (5.6) 1 (5.6) 1 (5.6) 1 (5.9) 1 (5.9) 1 (5.9)
Ezetimibe, n (%) 1 (2.9) 0 (0) 0 (0) 0 (0) 1 (5.9) 1 (5.9) 1 (5.9)
Antihypertensive drugs
Calcium channel blocker, n (%) 21 (60.0) 11 (61.1) 11 (61.1) 11 (61.1) 10 (58.8) 10 (58.8) 10 (58.8)
ARB, n (%) 20 (57.1) 11 (61.1) 11 (61.1) 11 (61.1) 9 (52.9) 10 (58.8) 10 (58.8)
ACE inhibitor, n (%) 5 (14.2) 3 (16.7) 3 (16.7) 3 (16.7) 2 (11.8) 1 (5.9) 1 (5.9)
Diuretic, n (%) 8 (22.9) 3 (16.7) 3 (16.7) 4 (22.2) 5 (29.4) 5 (29.4) 5 (29.4)
Beta-blocker, n (%) 8 (22.9) 4 (22.2) 4 (22.2) 4 (22.2) 4 (23.5) 5 (29.4) 5 (29.4)
Others
Antiplatelet agent, n (%) 18 (51.4) 7 (38.9) 7 (38.9) 7 (38.9) 11 (64.7) 12 (70.6) 12 (70.6)
  1. HDL high-density lipoprotein; ARB angiotensin receptor blockers; ACE angiotensin converting enzyme
  2. * P < 0.05 vs. control group